A 12-Week Multicenter, 2-Arm Regimen, Exploratory Study to Evaluate the Tolerability and Safety of Valsartan Administered Once Daily vs Daily, in Patients With Stable, Chronic Heart Failure (NYHA Class Ll-lll).

Trial Profile

A 12-Week Multicenter, 2-Arm Regimen, Exploratory Study to Evaluate the Tolerability and Safety of Valsartan Administered Once Daily vs Daily, in Patients With Stable, Chronic Heart Failure (NYHA Class Ll-lll).

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2011

At a glance

  • Drugs Valsartan (Primary)
  • Indications Chronic heart failure
  • Focus Adverse reactions
  • Acronyms DESTINY-HF
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2011 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
    • 29 May 2007 Status change
    • 22 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top